Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
Holding IMMP?
Track your performance easily
IMMP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.58 - $3.34
Previous Close$2.05
Volume55.63K
Average Volume (3M)276.29K
Market Cap
$309.70M
Enterprise Value$227.11M
Total Cash (Recent Filing)AU$123.42M
Total Debt (Recent Filing)AU$1.23M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Feb 20, 2025EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding1,187,306,209
10 Day Avg. Volume91,665
30 Day Avg. Volume276,285
Standard Deviation0.21
R-Squared0.29
Alpha0.00304
Financial Highlights & Ratios
Price to Book (P/B)18.64
Price to Sales (P/S)1001.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.67Price Target Upside328.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Immutep News
PremiumCompany Announcements
Immutep Advances Breast Cancer Immunotherapy Trial
PremiumCompany Announcements
Immutep’s Efti Shows Promise in Cancer TherapyPremiumCompany Announcements
Immutep: Quarterly Rebalance of S&P/ASX Indices
PremiumCompany Announcements
Immutep Reports Increased Loss Despite Higher IncomeBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEfti with pembrolizumab has shown a significant improvement in median overall survival in non-small cell lung cancer, surpassing the current standard of care in clinical trials.
Market PotentialWith multiple catalysts on the horizon and a current market cap of $364 million, Immutep Limited presents considerable upside potential for investors.
Product DevelopmentImmutep Limited is advancing its lead product candidate, eftilagimod alpha (efti), for multiple cancer indications, offering potential breakthroughs in oncology treatment.
Bears Say
Competitive LandscapeThe 1L metastatic HNSCC space has become very competitive.
Efficacy ConcernsThe eft/pembro combo ORR does not appear as impressive as some recent peer data reported at this year’s ASCO.
Study ResultsThe randomized arm of TACTI-003 is viewed as a 'failed study' since there was no clear signal for Phase 3.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.56% Other Institutional Investors
98.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.58 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Currently, no data Available
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 20, 2025 which is in 135 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 28, 2024. The company reported -$0.121 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.004.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -$0.15.
How many shares outstanding does Immutep have?
Immutep has 145,456,790 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.121 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went up 5.021%.
Which hedge fund is a major shareholder of Immutep?
Among the largest hedge funds holding Immutep’s share is Oracle Investment Management Inc. It holds Immutep’s shares valued at N/A.
---
Immutep Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (328.15% Upside)
$8.67 (328.15% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.41%
12-Months-Change
Fundamentals
Return on Equity
-25.75%
Trailing 12-Months
Asset Growth
37.16%
Trailing 12-Months
Company Description
Immutep
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$8.67
▲(328.15% Upside)
Technical Analysis
Best Analysts Covering IMMP
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+5.53%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +5.53% per trade.
---